<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046939</url>
  </required_header>
  <id_info>
    <org_study_id>KNS-760704-AS201</org_study_id>
    <nct_id>NCT04046939</nct_id>
  </id_info>
  <brief_title>Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma</brief_title>
  <acronym>AS201</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Knopp Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Knopp Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging,&#xD;
      multi-center study to evaluate the clinical effects of oral administration of dexpramipexole&#xD;
      for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred subjects will receive study drug or matching placebo over 12 weeks of consecutive&#xD;
      dosing. Following a short Run-in Period, eligible subjects will enter the Primary Assessment&#xD;
      Period and receive twice-daily dosing of study drug or placebo for 12 weeks. Following 12&#xD;
      weeks of treatment, subjects will enter a 12-week Eosinophil Recovery Period. The primary&#xD;
      endpoint for the study is the change in blood absolute eosinophil count from Baseline to Week&#xD;
      12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Actual">March 2, 2021</completion_date>
  <primary_completion_date type="Actual">December 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Four-arm parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood absolute eosinophil count from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood absolute eosinophil count will be collected at each study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pre-bronchodilator FEV1 from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Control Questionnaire (ACQ-7) score from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>ACQ-7 is simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment. The 7-point self-administered scale has items measuring asthma symptoms, rescue inhaler use, and FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post-bronchodilator FEV1 from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Post-bronchodilator FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation, after treatment with inhaled albuterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life, as measured by the Asthma Quality of Life Questionnaire (AQLQ) from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma. The 32 questions in the AQLQ are divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in pharyngeal and nasal eosinophil peroxidase concentration from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pharyngeal and nasal eosinophil peroxidase is a biomarker for respiratory tissue eosinophils.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood absolute blood basophil count from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood eosinophil progenitor population from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in fractional exhaled nitric oxide (FeNO) from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>FeNO is non-invasive biomarker of airway inflammation in asthma participants.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Eosinophilic Asthma</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>dexpramipexole 75 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexpramipexole 37.5 mg tablets taken orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexpramipexole 150 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexpramipexole 75 mg tablets taken orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexpramipexole 300 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexpramipexole 150 mg tablets taken orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo tablet taken orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexpramipexole 75 mg/day</intervention_name>
    <description>dexpramipexole low-dose BID</description>
    <arm_group_label>dexpramipexole 75 mg/day</arm_group_label>
    <other_name>KNS-760704</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexpramipexole 150 mg/day</intervention_name>
    <description>dexpramipexole mid-dose BID</description>
    <arm_group_label>dexpramipexole 150 mg/day</arm_group_label>
    <other_name>KNS-760704</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexpramipexole 300 mg/day</intervention_name>
    <description>dexpramipexole high-dose BID</description>
    <arm_group_label>dexpramipexole 300 mg/day</arm_group_label>
    <other_name>KNS-760704</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo oral tablet</intervention_name>
    <description>placebo BID</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥18 and &lt;75 years of age at the time of consent&#xD;
&#xD;
          -  Physician diagnosis of asthma for ≥12 months (relative to Baseline) based on Global&#xD;
             Initiative for Asthma (GINA) 2018 Guidelines&#xD;
&#xD;
          -  Asthma requiring treatment with, at a minimum, low dose inhaled corticosteroids in&#xD;
             combination with a long-acting β2 agonist, on a stable dose for at least 1 month&#xD;
             before Screening&#xD;
&#xD;
          -  Bronchodilator reversibility, as evidenced by ≥12% and ≥200 mL improvement in FEV1 15&#xD;
             to 25 minutes following inhalation of albuterol at Screening&#xD;
&#xD;
          -  Pre-bronchodilator FEV1 ≥40% and &lt;80% of predicted at Screening and Baseline&#xD;
&#xD;
          -  AEC ≥0.30 x10^9/L at the Screening visit&#xD;
&#xD;
          -  ACQ-7 ≥1.5 at Screening&#xD;
&#xD;
          -  Negative pregnancy test at Baseline&#xD;
&#xD;
          -  Adherence ≥85% with twice-daily placebo taken during the Run-in Period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment for an asthma exacerbation within 8 weeks prior to Baseline visit&#xD;
&#xD;
          -  Treatment with systemic corticosteroids in the 8 weeks prior to Screening&#xD;
&#xD;
          -  Treatment with monoclonal antibody therapy, within 5-half-lives prior to Baseline&#xD;
&#xD;
          -  Treatment with selected drugs known to have a substantial risk of neutropenia&#xD;
&#xD;
          -  Absolute neutrophil count &lt;2.0x10^9/L at Screening, or any documented history of&#xD;
             absolute neutrophil count &lt;2.0x10^9/L.&#xD;
&#xD;
          -  Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) &lt;60&#xD;
             mL/min/1.73m^2 at Screening&#xD;
&#xD;
          -  Clinically significant abnormal laboratory or ECG values&#xD;
&#xD;
          -  Other medically significant illness&#xD;
&#xD;
          -  Use of any smoke or inhaled nicotine delivery device within 1 year prior to Screening&#xD;
&#xD;
          -  Pregnant women or women breastfeeding&#xD;
&#xD;
          -  Currently taking pramipexole or other dopamine agonists&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winder</city>
        <state>Georgia</state>
        <zip>30680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophilic Asthma</keyword>
  <keyword>Asthma</keyword>
  <keyword>dexpramipexole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

